Avraham Naider - Loxo Oncology Independent Director
Director
Mr. Avraham Z. Naider, is Independent Director of Loxo Oncology. Inc. Mr. Naider has served as a member of our board of directors since September 2013. Mr. Naider is Chairman and CEO of ACES Risk Management Corporationration, a software company, a position he has held since January 2008. Mr. Naider is also a private investor and consultant to various companies. Prior to joining ACES, Mr. Naider founded an internet advertising software company, worked in private equity and was an associate at the Boston Consulting Group. Mr. Naider received his A.B. in the Woodrow Wilson School of Public and International Affairs from Princeton University. since 2013.
| Age | 44 |
| Tenure | 11 years |
| Phone | 203 653-3880 |
| Web | www.loxooncology.com |
Loxo Oncology Management Efficiency
Loxo Oncology's management efficiency ratios could be used to measure how well Loxo Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Barbara Samardzich | BRP Inc | 60 | |
| Vicki Sato | BorgWarner | 71 | |
| Eugene Katz | Asbury Automotive Group | 73 | |
| Dennis Cuneo | BorgWarner | 70 | |
| Eddie Sander | BorgWarner | N/A | |
| Sara Greenstein | BorgWarner | 46 | |
| Sandra Pierce | American Axle Manufacturing | 62 | |
| Elizabeth Chappell | American Axle Manufacturing | 63 | |
| Mark Schulz | Dana Inc | 63 | |
| John Smith | American Axle Manufacturing | 70 | |
| Joshua Bekenstein | BRP Inc | 59 | |
| Roger Krone | BorgWarner | 60 | |
| Dennis Clements | Asbury Automotive Group | 73 | |
| Forest Farmer | American Axle Manufacturing | 72 | |
| John Holder | Genuine Parts Co | 66 | |
| Kevin Penn | American Axle Manufacturing | N/A | |
| Ernest Novak | BorgWarner | 71 | |
| Jan Carlson | BorgWarner | 58 | |
| Paul Mascarenas | BorgWarner | 59 | |
| Gary Fayard | Genuine Parts Co | 69 | |
| Diarmuid Connell | Dana Inc | 53 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 |
Loxo Oncology Leadership Team
Elected by the shareholders, the Loxo Oncology's board of directors comprises two types of representatives: Loxo Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Loxo. The board's role is to monitor Loxo Oncology's management team and ensure that shareholders' interests are well served. Loxo Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Loxo Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jacob Naarden, VP of Corporate Devel. and Strategy | ||
| James Barrett, Independent Director | ||
| Timothy Mayleben, Independent Director | ||
| Jennifer Low, Chief Medical Officer | ||
| Joshua Bilenker, President CEO, Director | ||
| Avraham Naider, Independent Director | ||
| Lori Kunkel, Director | ||
| David Bonita, Independent Director | ||
| Jennifer Burstein, Vice President - Finance, Principal Financial Officer and Principal Accounting Officer | ||
| Keith Flaherty, Director | ||
| Steven Elms, Independent Director | ||
| Alan Fuhrman, Independent Director | ||
| Steven Harr, Independent Director | ||
| Sara Slifka, Sr. Director of Operations | ||
| Nisha Nanda, VP of Devel. Strategy |
Loxo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Loxo Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.0059 | |||
| Profit Margin | (43.49) % | |||
| Operating Margin | (50.33) % | |||
| Current Valuation | 6.56 B | |||
| Shares Outstanding | 30.75 M | |||
| Shares Owned By Insiders | 3.70 % | |||
| Shares Owned By Institutions | 92.93 % | |||
| Number Of Shares Shorted | 1.03 M | |||
| Price To Earning | (20.33) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Loxo Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Loxo Oncology's short interest history, or implied volatility extrapolated from Loxo Oncology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Loxo Stock
If you are still planning to invest in Loxo Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Loxo Oncology's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |